Show simple item record

dc.contributor.authorOnat, O. E.en_US
dc.contributor.authorTez, M.en_US
dc.contributor.authorÖzçelik, T.en_US
dc.contributor.authorTörüner, G. A.en_US
dc.date.accessioned2016-02-08T10:18:16Z
dc.date.available2016-02-08T10:18:16Z
dc.date.issued2006en_US
dc.identifier.issn0250-7005
dc.identifier.urihttp://hdl.handle.net/11693/23727
dc.description.abstractRecently, a functional T to G polymorphism at nucleotide 309 in the promoter region of the MDM2 gene (rs: 2279744, SNP 309) has been identified. This polymorphism has an impact on the expression of the MDM2 gene, which is a key negative regulator of the tumor suppressor molecule p53. The effect of T309G polymorphism of the MDM2 gene on bladder cancer susceptibility was investigated in a case-control study of 75 bladder cancer patients and 103 controls from Turkey. The G/G genotype exhibited an increased risk of 2.68 (95% CI, 1.34-5.40) for bladder cancer compared with the combination of low-risk genotypes T/T and T/G at this locus. These results show an association between MDM2 T309G polymorphism and bladder cancer in our study group. To the best of our knowledge, this is the first study reporting that MDM2 T309G polymorphism may be a potential genetic susceptibility factor for bladder cancer.en_US
dc.language.isoEnglishen_US
dc.source.titleAnticancer Researchen_US
dc.subjectBladder canceren_US
dc.subjectCancer predispositionen_US
dc.subjectCase-control studyen_US
dc.subjectMDM2 polymorphismen_US
dc.subjectAdulten_US
dc.subjectAgeden_US
dc.subjectArticleen_US
dc.subjectBladder canceren_US
dc.subjectCancer risken_US
dc.subjectCase control studyen_US
dc.subjectConfidence intervalen_US
dc.subjectControlled studyen_US
dc.subjectDisease associationen_US
dc.subjectGene expressionen_US
dc.subjectGenetic polymorphismen_US
dc.subjectGenetic susceptibilityen_US
dc.subjectGenotypeen_US
dc.subjectHumanen_US
dc.subjectMajor clinical studyen_US
dc.subjectPriority journalen_US
dc.subjectPromoter regionen_US
dc.subjectTopographyen_US
dc.subjectTurkey (republic)en_US
dc.subjectAdulten_US
dc.subjectAgeden_US
dc.subjectAged, 80 and overen_US
dc.subjectCase-Control studiesen_US
dc.subjectDNA Mutational analysisen_US
dc.subjectFemaleen_US
dc.subjectGenotypeen_US
dc.subjectHumansen_US
dc.subjectMaleen_US
dc.subjectMiddle ageden_US
dc.subjectOdds ratioen_US
dc.subjectPolymorphism, Single nucleotideen_US
dc.subjectPromoter regions (Genetics)en_US
dc.subjectProto-Oncogene Proteins c-mdm2en_US
dc.subjectRisk factorsen_US
dc.subjectUrinary bladder neoplasmsen_US
dc.titleMDM2 T309G polymorphism is associated with bladder canceren_US
dc.typeArticleen_US
dc.departmentDepartment of Molecular Biology and Geneticsen_US
dc.departmentInstitute of Materials Science and Nanotechnology (UNAM)en_US
dc.citation.spage3473en_US
dc.citation.epage3475en_US
dc.citation.volumeNumber26en_US
dc.citation.issueNumber5 Aen_US
dc.publisherInternational Institute of Anticancer Researchen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record